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Summary 
Antigen priming of naive CD4 T cells can generate effector CD4 T cells that produce interleukin 
4 (T helper [Th]2-1ike) or interferon-y (Thl-like).  Using a system in which priming leads to 
responses dominated by one or the other of these cell types, we show that varying either the 
antigenic peptide or the major histocompatibility complex class II molecule can determine whether 
Thl-like or Th2-1ike responses are obtained. Our results show that peptide/major histocompati- 
bility complex class II complexes that interact strongly with the T cell receptor favor generation 
of Thl-like cells, while those that bind weakly favor priming of Th2-1ike  T  cells. Thus, signals 
from the T  cell receptor can influence the differentiation of CD4 T  cells into specific types of 
effector cells. 
T 
he type of effector CD4 T lymphocyte activated during 
an adaptive immune response determines the efficacy of 
the response in protective immunity to pathogens.  This, in 
turn, is controlled by selective generation of distinct subsets 
of effector CD4 T  cells  (1,  2) known as Thl  cells,  which 
can activate macrophages  and release,  upon activation,  the 
cytokines IFN-'y and lymphotoxin (3-5), and Th2 cells, which 
induce B cells to secrete IgG1 and IgE antibodies and pro- 
duce the cytokines II,-4 and  I1.-5 (2,  6,  7).  While little  is 
known about the mechanisms by which selective differentia- 
tion of naive CD4 T  cells into Thl  or Th2 effector cells is 
achieved,  cytokines produced in the early phases of some in- 
fections clearly have an impact on this process (8-16). In this 
report,  we show that  the selective generation  of a CD4 T 
cell functional class can also be influenced by the nature of 
the antigen itself. Specifically, we show that subtle modifica- 
tions in a peptide used for primary  immunization  in vivo 
can lead to selective generation of Thl or Th2 cells.  Thus, 
signals  delivered  via  the  TCR  can  influence  CD4  T  cell 
differentiation. 
In earlier studies, we have shown that mice primed with 
human collagen IV (huCollV) developed either IL-4-secreting 
Th2 cells or IFN-'y-secreting Thl cells, depending on their 
genotype at MHC class II (17,  18).  Strains  of mice having 
the MHC class II molecule I-A  b produced serum antibody 
in response to huCollV,  but did not prime T  cells  which 
would proliferate in a secondary response. This was in con- 
trast  to  mice  expressing  I-A  s,  whose  T  cells  proliferated 
upon rechaUenge,  but did not induce an antibody response. 
This difference was due to selective activation  of Th2-1ike 
CD4 T  cells in H-2  b mice and Thl-like CD4 T  cells in H-2  s 
mice  (18).  Both  mouse  strains  responded  to  a  single  12- 
amino  acid peptide within  the huCollV molecule (19) by 
generating their characteristic set of CD4 T  cells (reviewed 
in  Table  1).  As  the  functional  class  of the  response  was 
influenced by the genotype of the MHC class II molecule, 
which presents peptides to CD4 TCR, we proposed that the 
ability of MHC class  II  genotype to control  CD4  T  cell 
differentiation could be due to differences in the repertoire 
of T cells responding to the antigen, or to differences in pep- 
tide/MHC  class  II  structure  and/or  abundance  (20).  The 
former seemed unlikely, because it would link MHC allele 
specificity to function and is now known to be wrong, since 
mice transgenic  for a known TCR can generate responses 
dominated  by either  Thl-  or  Th2-1ike  cells  that  use  the 
transgene-encoded  receptor  (21,  22).  We  have,  therefore, 
focussed upon the latter possibility, both by measuring the 
strength  of binding  of the  immunodominant  peptide  of 
huColIV to purified MHC class IX molecules and by examining 
the  effect of peptide  modification  on  CD4  T  cell  subset 
differentiation. Our results show that the nature of the ligand 
for the TCK can control the differentiation  of naive  CD4 
T  ceils into  committed effector cells. 
Materials  and Methods 
Animals.  A.SW/SnJ and A.BY/SnJ mice were purchased from 
The Jackson Laboratory (Bar Harbor,  ME) and used at 6-12 wk 
of age. 
Antigens.  Synthetic peptides coding for residues 675-686 of the 
alpha chain of huCollV were prepared by solid phase chemistry 
on a peptide synthesizer (model 430-A; Applied Biosystems, Inc., 
Foster City,  CA),  and were purified by HPLC. 
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cultured, as previously described (18), from mice immunized 10 d 
previously. 
Peptide Binding Assays.  I-A +  and I-A b molecules  were purified, 
as previously described (23, 24). The relative avidity was measured 
by competing binding of radiolabeled  reference peptide (ROW), 
to purified I-A' or I-AL 
Cytokine mRNA  Expression.  cDNA  was  amplified  with  35 
cycles of PCR (94  ~ for 1 min, 60 ~ for 2 min, 72 ~ for 3 min), using 
Taq polymerase (Promega Corp., Madison,  WI). PCK products 
were run on 2% agarose gel by electrophoresis.  Control cDNA 
was prepared from the activated Thl clone, C19,  which secretes 
IFN-% but not Ib4, upon activation; the activated Th2 clone, D10, 
which secretes ID4, but not IFN-% upon activation; and CD4 
T  cells from KLH-primed mice. Primers: IFN-'y (sense) 5'-TGA- 
ACGCTACACACTGCATCTTGG and (antisense)  5'-CGACTC- 
CTTTTCCGCTTCCTGAG; IL-4 (sense) 5'-ATGGGTCTCAAC- 
CCCCAGCTAGT  and  (antisense)  5'-GCTCTTTAGGCTTTC- 
CAGGAAGTC; CD3~ (sense) 5'-GCAGCTGGCAAAGGTGGT- 
GTCTTC and (antisense) 5'-~AC'ITIGAGAAACCrCCAT. 
Cytokine Bioassays.  For Ib2 measurement, serial dilutions of 
supematant from cultures described  above were added  to 10,000 
CTL line indicator cells in the presence  or absence of anti-IL-2 
antibody. Cultures were pulsed after 48 h with 1 #Ci [3H]dTdR 
and harvested 18-24 h later. Standard  plates were set up with sev- 
eral titrations of recombinant routine IL-2, and units were calcu- 
lated from standard  curves with one unit being defined as the 
amount of Ib2 that gave half-maximal proliferation. For IFN-3, 
measurement, dilutions of supernatant were incubated with 5,000 
WEHI-279 cells in the presence or absence of anti-IFN-'y anti- 
bodies.  Proliferation was assessed after 48 h, with 1 U of IFN-y 
defined as the concentration which gave half-maximal inhibition 
of WEHI-279 proliferation, calculated from the standard curve ob- 
tained with mouse IFN-~/standard (Genzyme Corp., Cambridge, 
MA).  In  all  assays, inhibition  of proliferation was  blocked by 
anti-IFN-% 
Results 
Relative Binding Avidity of huCollV Peptides to MHC Class 
II.  The binding of the immunodominant huColIV peptide 
to MHC  class  II  I-A s and  I-A  b molecules was  determined 
using affinity-purified MHC class II molecules extracted from 
B lymphoma cells (23, 24). The same reference peptide (ROW) 
was  used as  a  labeled probe for binding  to both  I-A  b and 
I-A',  and its ability as a cold peptide inhibitor was used to 
standardize binding to the two different MHC class II mole- 
cules.  ROW  bound both  I-A s and  I-A  b well (Fig.  1) with 
ICs0 in the 20-40 nM range.  Other controls in the experi- 
ments were the I-As-restricted epitope myelin basic protein 
81-100  (25),  which bound  I-A  + as well as the ROW  pep- 
tide, but bound with far less affinity for I-A  b, and the I-A  d- 
restricted peptide staphylococcal nuclease 91-100 (26), which 
bound  both  I-A  b and  I-A s with  ICs0  in  the  0.5-1.0  #M 
range.  Using this assay,  it can be seen (Fig.  1) that the im- 
munodominant  peptide  of huCollV  (wild-type)  binds  to 
I-A  s 2  x  10a-fold more avidly than it binds to I-A  b. These 
data are consistent with the hypothesis that presentation of 
different densities of huCollV peptide to T  cells can lead to 
selective priming of Thl or Th2, as observed in earlier studies 
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Figure 1.  Relative avidity of I-A  s- and I-Ab-binding peptides. The rel- 
ative avidity was measured by competing binding of ROW to purified 
I-A  +  or I-AL The amount (#M) of each peptide (wild-type, ol21675-686] 
huCollV; MBP, myelin  basic protein peptide 81-100; Nase, Staphylococcus 
nuclease 91-110; ROW, superbinder used as the reference  peptide because 
it binds both I-A  s and I-A  b well) required to inhibit the binding of the 
ROIV (23, 24) to either I-A  + (top) or I-A  b (bottom) is shown. 
(20).  When  mice of I-A  b genotype were immunized with 
progressively higher doses of huColIV wild-type peptide, we 
did indeed observe a shift from Th2 to Thl.  Likewise, in- 
creasing the dose of peptide injected into I-A  s eventually shut 
down the production of Thl cytokines. However, we did not 
observe a dose of huColIV peptide at which the H-2 s mice 
developed CD4 T  ceils making Th2 cytokines. Thus, it ap- 
pears that dose of MHC/peptide by itself cannot control Thl 
versus Th2  differentiation. 
Mutant ColIV Peptides that Elicit IL.4, Rather than IFN-'/, 
responses from  CD4  Cells in 1-,4  s Mice.  The problem with 
this type of analysis is that I-A  b and I-A  s molecules differ by 
many amino acid residues,  and the responding T  ceils have 
developed under different intrathymic  selective conditions. 
Thus, it is difficult to make direct comparisons of T  cell re- 
sponses between strains, even if they differ only at the MHC. 
To circumvent this difficulty, we have prepared mutants  of 
the huColIV  immunodominant  peptide that differ in their 
binding  to  I-A + or  I-A  b,  but  nevertheless  could  activate  a 
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to the appropriate MHC class II molecules, as shown in Figs. 
2 and 3. These peptides were then tested for their ability to 
prime Thl- or Th2-1ike CD4 T cells in a single strain of mouse. 
Two mutant peptides, c~2Glu(5) and ot2Ala(ll), which re- 
quired higher concentrations than the wild-type peptide to 
activate  a  panel  of I-As-restricted,  huCollV-specific T  cell 
hybridomas were identified (Fig. 2 A).  These peptides also 
bound to I-A  ~ somewhat less well than the wild-type pep- 
tide. Purified CD4 T cells from mice primed with c~2Glu(5), 
o~2Ala(ll), or the wild-type peptide were analyzed for their 
ability to proliferate to the wild-type peptide in vitro, presented 
by antigen-presenting cells from I-A  s mice. As can be seen 
in  Fig.  2  B,  CD4  T  cells  from  c~2Ala(11)  and  a2Glu(5) 
showed little, if any, proliferative response in comparison to 
the response of CD4 T  cells from H-2 s mice primed with 
the wild-type peptide. Messenger RNA (mKNA) was also 
isolated from the CD4 T  cells in these secondary cultures, 
reverse transcribed into cDNA, and assayed by cytokine~specific 
polymerase chain reaction for cytokine-specific mRNA.  As 
shown in Fig. 2 C, mKNA specific for IFN-% but not IL-4, 
was  produced by  CD4  T  cells from H-2 ~ mice  that  were 
primed with the wild-type peptide, but not from CD4 T  cells 
primed with the mutant peptides, a2Ala(11) and o~2Glu(5), 
and restimulated with  the wild-type peptide.  By contrast, 
IL-4 mRNA appeared only in CD4 T  cells from H-2 s mice 
primed with a2Ala(11)  and o~2Glu(5)  and restimulated by 
the wild-type peptide. Thus, a decrease in the ability of the 
MHC class II/peptide complex to activate a group of huCollV- 
specific T  cell hybridomas led to a change in the differentia- 
tion of naive CD4 T  cells upon priming,  as reflected in a 
change  in  cytokines  produced  from  IFN-3,  to  ILo4. This 
change correlates much better with the differences in the ability 
to  activate  a  panel  of  hybridomas  specific  for  wild-type 
huCollV  than with binding to I-A  s. 
Mutant huCollV Peptides that Stimulate I-A b-specific Hybrids 
lO0-fold  Better  Can  Prime  Thl-like  CD4  T  Cells  in  1-1-2  b 
Mice.  To analyze CD4 T  cell differentiation in H-2  b mice, 
one peptide with an Ala substitution at position 10, o~2Ala(10), 
was identified that had an 80-fold increased ability to acti- 
vate a panel of H-2b-restricted  huCollV-specific T  cell hy- 
bridomas  (Fig.  3 A).  Its  ability  to bind  I-A  b was  not dis- 
tinct  from that  of the wild-type huCollV peptide.  When 
c~2Ala(10)  was used to prime H-2  b mice, the CD4  T  cells 
revealed an excellent recall proliferative response to the wild- 
type  peptide  presented  by  H-2  b  antigen-presenting  cells, 
whereas priming with the wild-type peptide did not (Fig. 
3 B).  Analysis of cytokine mKNA  expression of the CD4 
T  cells restimulated in vitro with wild-type peptide demon- 
strated that CD4 T  cells from mice primed with the wild- 
type peptide made IL-4, but not IFN-'r,  mRNA,  as shown 
previously (Table 1), but CD4 T cells from mice primed with 
the  mutant  peptide  ol2Ala  (10)  no  longer  expressed  IL-4 
mKNA, but IFN-'r mKNA (Fig. 3  C).  Thus, in this case 
Figure 2.  Immunization  with mutant peptides changes the type of effector CD4 T cell generated during priming of H-2  S  mice. (A) Summary of 
the I-A  S mutant peptides. Peptide binding is determined by the amount of peptide (~tM) required to inhibit the binding of KOIV to I-A~  by 50% 
(IC50). The response of the huCollV-specific, l-As-restricted T cell hybridoma is determined by culturing 2  x  10  s T  hybridoma cells and 2  x  10s 
irradiated T-depleted spleen cells with varying concentrations  of peptide. After 24 h, supernatants were collected and analyzed for presence of IL-2, 
using the CTL line 11:2 bioassay. The peptide concentration (#g/ml) required for the release of 1 U  I1:2/culture  is used to compare T  hybridoma 
activation by wild-type and mutant peptides. The data represent one of five individual  experiments giving the same results. (B) The proliferative response 
of CD4 T cells from wild-type and mutant peptide-primed H-2  s (A.SW) mice. CD4 T  cells were isolated, as described previously (18), from mice 
immunized 10 d previously with 2 #g. 2  x  10  s CD4 T cells/well were cultured with the wild-type peptide (0.05-50 #g/ml) and 2  x  105 T-depleted 
splenocytes (mitomycin C-treated) as antigen presenting  cells. Cultures were incubated for 72 h, followed by an overnight  pulse with 1 #Ci/weU 
[3H]thymidine. The background cpm without antigen was <  1,500 and has been subtracted from the results. Plotted values represent mean +  SD 
of triplicate cultures.  All experiments  were repeated at least three  times.  (C) Cytokine mKNA expression upon priming H-2  s (A.SW)  mice with 
mutant and wild-type peptides. CD4 T cells from mutant and wild-type peptide-primed H-2  S  (A.SW) mice (primed with 2 #g peptide/mouse)  were 
isolated from the local lymph nodes and were cultured in 24-well plates at 2  x  106 cells/well in the presence of 10 #g/ml wild-type peptide and 1 ￿ 
106 syngeneic T-depleted splenocytes (mitomycin C-treated) from normal, nonimmunized, syngeneic mice. After 48 h, mKNA was made (Micro-Fast 
Track; Invitrogen, San Diego,  CA); cDNA from 2  x  104 cells was prepared and used for each PCR and was equalized using CD3/~ as a control. 
These sequence data are available from GenBank/EMBL/DDBJ under accession numbers K00083  (IFN-3~), X05064  (IL-4), and X02339  (CD3~). 
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of the l-Ab-binding peptides. Peptide binding is determined as described in the Fig. 2 legend and Materials and Methods. The response of the huCollV- 
specific, l-Ab-restricted hybridoma was determined as described in the Fig. 2 legend. (B) The proliferative response of CD4 T cells from wild-type 
and mutant peptide-primed H-2  b (A.BY) mice (see Fig. 2 legend). (C) Cytokine mRNA expression upon priming of H-2  b (A.BY) mice with mutant 
and wild-type peptides (see Fig. 2 legend and Materials and Methods). 
as well,  the ability of an huCollV  peptide to interact  with 
MHC  and  the TCR  gives rise  to a  phenotypically distinct 
response. 
Priming Dose of  Peptide Regulates the Type of Effector CD4 
T  Cells Response in 1-1-2  ~.  Given  that  our  initial  findings 
showed that increasing the priming dose of huCollV  wild- 
type peptide in H-2  s leads to a shift from Th2 to Thl  cells 
(20), and given that the mutant peptide ot2Ala(ll) could prime 
Th2  cells  in  H-2  s mice,  we  tested  whether  increasing  the 
priming dose of a2Ala(11) would lead to a shift in priming 
from Th2  to  Thl  cells  in  H-2  ~ mice  as well.  CD4  T  cells 
from mice primed with  either  2/~g  or 50/~g  of wild-type 
or mutant peptides were analyzed for I1:4 or IFN-3' produc- 
tion in vitro upon restimulation with the wild-type peptide. 
As  can  be  seen  in  Fig.  4,  mRNA  specific  for  IFN-y  and 
IFN-y protein were observed after restimulation  when  the 
CD4 T cells were derived from wild-type or ot2Ala(ll) primed 
mice.  No  I1:4 was observed from these same primed CD4 
T  cells. However, when CD4 T  cells were derived from mice 
primed with 2 #g ofpeptide, the CD4 T cells from ot2Ala(ll)- 
primed mice shifted from IFN-3' to II:4 production, whereas 
the CD4 T  cells from wild-type peptide-primed mice pro- 
duced IFN-3'.  These data,  taken together,  suggest  that  the 
real variable in this system is the interaction of the peptide/ 
MHC class II complex with the TIER, and that this can be 
adjusted either through altered binding to MHC, or through 
altered  binding  of the  complex  to  a  TCR. 
Discussion 
These  studies  show  that  the  nature  of  the  complex 
ligand-comprising peptide bound to an MHC class II mole- 
Table  1.  Summary  of Characteristics of Murine Response 
to huCollV 
Type of response of  MHC  class  II 
CD4  T  cells  genotype 
b 
Proliferation 
T  cell help  for antibody 
formation  (IgG1)  +  +  + 
Cytokine expression 
IL-2  + 
IFN-y 
IL-4  +  + 
IL-5  +  + 
S 
+++ 
+++ 
+++ 
Figure  4.  Increasing  the priming dose changes the type of effector  CD4 
T cells generated in H-2' mice. CD4  T  cells from H-2  s (A.SW) mice 
primed with 50 ~g (A) or 2/~g (B) of mutant or wild-type peptide were 
analyzed for cytokine mRNA expression, as described in Fig. 2. Superna- 
tants were tested for IFN-y production,  as described in Materials and 
Methods, and yielded the following results: Priming with:  50/~g-wild- 
type peptide =  27 U/ml; ot2Ala(ll) mutant peptide =  6 U/ml; priming 
with: 2 #g-wild-type peptide =  18 U/ml; c~2Ala(11) mutant peptide  = 
< limits of detection. The limit of detection in this experiment was 0.5 
U/ml rlFN-y. No Ib4 was detected by bioassay, as has been reported pre- 
viously (18). 
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differentiation of naive CD4 T  cells into Thl-like or Th2- 
like cells. It appears that when used at a single dose, peptides 
that bind well to MHC class II molecules and/or to the TCR 
lead selectively to Thl-like cells, while peptides that bind less 
well prime Th2-1ike cells. It can be argued that CD4 T cells 
of different specificity are primed by wild-type and mutant 
peptides, both of which recognize the wild-type peptide upon 
secondary challenge. While this would account for the selec- 
tive priming of Thl- and Th2-1ike  cells, we feel that T  cell 
specificity does not determine effector cell type, since mice 
carrying TCR transgenes can develop either Thl-  or Th2- 
like responses (21,  22,  27). 
The present studies show that similar effects occur with 
in vivo priming, which may account for the surprising finding 
that MHC class II genotype can control the functional differen- 
tiation of CD4 T cells in response to huCollV. The implica- 
tion of this finding is twofold. Firstly, it suggests that signals 
delivered via the TCR can control the differentiation of CD4 
T cells into their selective effector cell types. How these signals 
differ is not  known;  it may be a quantitative  difference in 
the intensity of signaling,  or it may reflect  the types of al- 
tered signaling that account for differential responses of ma- 
ture T cells to peptides and their variants (28-31). A simple 
view of the mechanism acounting for the generation of dis- 
tinct effector functions is that the extent of TCR aggrega- 
tion leads to different intracellular signals. This might be due 
to differences in the threshold of signals needed for distinct 
cytokine gene expression, which may in turn be controlled 
by TCR occupancy. Alternatively,  it  might  be due to the 
differential  participation of costimulatory molecules. If TCR 
aggregation  is  inefficient,  there  may  be  a  corresponding 
deficiency in the induction of costimulatory molecules im- 
portant  in the selective generation  of Thl  or Th2 T  cells. 
Secondly, these results suggest that high MHC class II/ 
peptide density on the antigen-presenting  cell surface favors 
Thl-like responses, while low ligand densities favor Th2-1ike 
responses.  If this interpretation  is correct, it has important 
implications for allergy. Allergens are not known to provoke 
inflammatory  reactions  that  would generate the cytokines 
necessary to promote Th2-1ike differentiation; however, they 
are presented to the human immune system at very low dose, 
leading to IgE synthesis. Moreover, desensitization is gener- 
ated by injecting successively higher doses of allergen. Like- 
wise, the highest ligand densities are likely to be generated 
by B cells binding  soluble protein  antigens  and by macro- 
phages infected with intracellular  pathogens. Priming in these 
cases appears to favor generation of Thl-like cells. Thus, the 
outcome of priming CD4 T  cells can be determined,  both 
by the cytokines present in the site of priming  and by the 
antigen itself. Which of these is more important  in a given 
immune  response must be determined  by direct  analysis. 
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